China Grand Pharmaceutical and Healthcare Holdings Limited

Grand Journey for A Healthier World

GP (HK) Announces Positive Profit Alert

The Expected Increase in Consolidated Net Profit Attributable to Owners of the Company for FY2020 No Less Than 40%

READ MORE

Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud

READ MORE

GP (HK)’s Associate OncoSec Enters into A Collaboration Agreement with Merck to Conduct a Global Phase III Study in Advanced Metastatic Melanoma. The R&D of TAVO™ Records Landmark Progress, Continuing to Consolidate the Strategic Planning in Anti-Tumor Immunology Field

GP (HK)’s Associate OncoSec Enters into A Collaboration Agreement with Merck to Conduct a Global Phase III Study in Advanced Metastatic Melanoma. The R&D of TAVO™ Records Landmark Progress, Continuing to Consolidate the Strategic Planning in Anti-Tumor Immunology Field

READ MORE

GP(HK) Global Innovative RDC TLX250-CDX Dosed the First Patient with the Expanding Indication in Australia, and the Self-developed “Tadalafil Tablets” is Granted a Drug Registration Certificate, Continuously Improving Research Strength and Enriching Its Product Pipelines

GP(HK) Global Innovative RDC TLX250-CDX Dosed the First Patient with the Expanding Indication in Australia, and the Self-developed “Tadalafil Tablets” is Granted a Drug Registration Certificate, Continuously Improving Research Strength and Enriching Its Product Pipelines

READ MORE

GP (HK) Subscribes for New Shares of Sirtex HoldCo and Reaches the TRS Agreements with Natixis. Further Increase Shareholding Rights in Sirtex and Strengthen the Group’s Product Pipeline in the Field of Tumor Precision Interventional

GP (HK) Subscribes for New Shares of Sirtex HoldCo and Reaches the TRS Agreements with Natixis. Further Increase Shareholding Rights in Sirtex and Strengthen the Group’s Product Pipeline in the Field of Tumor Precision Interventional

READ MORE

GP (HK) Obtains Exclusive Development and Commercialization Rights of Improved New Drug for Anti-inflammatory and Pain Relief after Ophthalmology Surgery, Enriches Its Product Pipeline of High-Barrier Drugs in the Ophthalmology Sector

GP (HK) Obtains Exclusive Development and Commercialization Rights of Improved New Drug for Anti-inflammatory and Pain Relief after Ophthalmology Surgery, Enriches Its Product Pipeline of High-Barrier Drugs in the Ophthalmology Sector

READ MORE

READ MORE

Popular News

27 Mar

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Results

READ MORE

27 Mar

Yuanda medicine gets sepsis innovative medicine again

READ MORE

27 Mar

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

READ MORE

27 Mar

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

READ MORE

Media Report

Yuanda medicine gets sepsis innovative medicine again

Shanghai Securities News China Securities Network2020-3-27